To the Editor We read with interest the Original Investigation from Yu et al1 wherein they reported results of a phase 1/2 trial to assess the effects of the combination of osimertinib and bevacizumab as first-line treatment for patients with metastatic EGFR-mutant lung cancers. However, the 19-month median progression-free survival (PFS) in the study was comparable with the median PFS with osimertinib alone (19 months) in the FLAURA study.2 We wish to put forth the following discussion points.
Qi C, Cui H, Chen D. Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers. JAMA Oncol. 2020;6(12):1982. doi:10.1001/jamaoncol.2020.4818
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.